CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
E1Y03 ECOG Master Protocol for Pharmacogenetic and Genomic Studies. Adult CIRB - Late Phase Emphasis
E2100 ECOG A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab (rhuMAb VEGF) as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer Adult CIRB - Late Phase Emphasis
E2108 ECOG A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer Adult CIRB - Late Phase Emphasis
E2112 ECOG A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer Adult CIRB - Late Phase Emphasis
E2212 ECOG A Randomized; Double-Blinded; Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver Adult CIRB - Early Phase Emphasis
E2499 ECOG Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Cell Lymphoma Adult CIRB - Late Phase Emphasis
E2603 ECOG A Double-blind; Randomized; Placebo-Controlled Phase III Trial of Carboplatin; Paclitaxel and Sorafenib Versus Carboplatin; Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma Adult CIRB - Late Phase Emphasis
E2805 ECOG ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma Adult CIRB - Late Phase Emphasis
E2810 ECOG Randomized; Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy Adult CIRB - Late Phase Emphasis
E2902 ECOG A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients over Age 60 in First Remission Adult CIRB - Late Phase Emphasis